NCT00407836View on ClinicalTrials.gov

Efficacy Study of T Cell Vaccination in HIV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
HIV Infections
Interventions
BIOLOGICAL

T cell vaccination

Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.

BIOLOGICAL

T cell vaccination

Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection

Trial Locations (1)

Unknown

Soroka Medical Center, Beersheba

All Listed Sponsors
lead

Soroka University Medical Center

OTHER

NCT00407836 - Efficacy Study of T Cell Vaccination in HIV Infection | Biotech Hunter | Biotech Hunter